Cell therapy for acute respiratory distress syndrome patients: the START study

Fernanda Ferreira Cruz^{1

2}, Patricia Rieken Macedo Rocco^{1

2}

Affiliations

¹ Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
² National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil.

Editorial

Fernanda Ferreira Cruz et al. J Thorac Dis. 2019 May.

. 2019 May;11(Suppl 9):S1329-S1332.

doi: 10.21037/jtd.2019.04.22.

Fernanda Ferreira Cruz^{1

2}, Patricia Rieken Macedo Rocco^{1

2}

¹ Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
² National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD. Matthay MA, et al. Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16. Lancet Respir Med. 2019. PMID: 30455077 Free PMC article. Clinical Trial.

1. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 2016;315:788-800. 10.1001/jama.2016.0291 - DOI - PubMed
1. Cruz FF, Weiss DJ, Rocco PR. Prospects and progress in cell therapy for acute respiratory distress syndrome. Expert Opin Biol Ther 2016;16:1353-60. 10.1080/14712598.2016.1218845 - DOI - PubMed
1. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014;2:1016-26. 10.1016/S2213-2600(14)70217-6 - DOI - PubMed
1. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3:24-32. 10.1016/S2213-2600(14)70291-7 - DOI - PMC - PubMed
1. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 2019;7:154-62. 10.1016/S2213-2600(18)30418-1 - DOI - PMC - PubMed